Amphastar Pharmaceuticals Inc. (AMPH) exhibits 49.5% gross margins and 9.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 9.4x enterprise multiple and 4.8% implied options volatility.
Sustained 49.5% gross profitability converts into 19.5% operating margin and 9.0% ROIC, outpacing sector cost of capital.
ROIC: 9.0% // GM: 49.5%YoY revenue trajectory of -1.7% paired with 10.58% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -1.7% // FCF YLD: 10.58%Altman Z-Score of 2.47 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.47 // F-SCORE: 7/9Trading at 11.7x trailing P/E (10.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 11.7x // EV/EBITDA: 9.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $27.03 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 13.6% net margins.
NET MARGIN: 13.6% // D/E: 0.79x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AMPH & activate live FRED threshold breach alerts.